In this study, we investigated the effects of proteinase gene disruption on heterologous protein production by Aspergillus oryzae. The human lysozyme (HLY) was selected for recombinant production as a model for the heterologous protein. A tandem HLY construct fused with alpha-amylase (AmyB) was expressed by A. oryzae in which the Kex2 cleavage site was inserted at the upstream of HLY. HLY was successfully processed from AmyB and produced in the medium. We performed a systematic disruption analysis of five proteinase genes (pepA, pepE, alpA, tppA, and palB) in the HLY-producing strain with the adeA selectable marker. Comparative analysis indicated that disruption of the tppA gene encoding a tripeptidyl peptidase resulted in the highest increase (36%) in the HLY production. We further deleted the tppA gene in the pepE or palB disruptant with another selectable marker, argB. Consequently, a double disruption of the tppA and pepE genes led to a 63% increase in the HLY production compared to the control strain. This is the first study to report that the double disruption of the tppA and pepE genes improved the production level of a heterologous protein by filamentous fungi.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00253-007-1088-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease.
J Alzheimers Dis
January 2025
Department of Vascular Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Alzheimer's disease (AD), the leading cause of dementia, is characterized by cognitive decline and the accumulation of amyloid-β (Aβ). It affects millions, with numbers expected to double by 2050. SMOC2, implicated in inflammation and fibrosis, may play a role in AD pathogenesis, particularly in microglial cell function, offering a potential therapeutic target.
View Article and Find Full Text PDFNeuroplasticity in the motor cortex following the achievement of sufficient motor learning.
Neurosci Lett
January 2025
Laboratory of Neurorehabilitation, Department of Occupational Therapy, Biwako Professional University of Rehabilitation, 967 Kitasaka, Higashiomi, Shiga 527-0145, Japan.
Skilled motor training causes the cortical representation of the trained body parts to expand into regions of the motor cortex related to other body parts. However, the effect of neuroplastic changes on the neurons originally existing within the expanded area is not well understood. In this study, the extent of the neuroplastic changes after achieving sufficient motor learning and the impact of the expansion on the neurons related to movements of other body parts were investigated.
View Article and Find Full Text PDFEscitalopram for Agitation in Alzheimer’s Dementia.
Alzheimers Dement
December 2024
School of Medicine, Johns Hopkins University, and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA
Background: Agitation is a common and disabling symptom of Alzheimer’s dementia (AD). Pharmacological treatments are recommended if agitation is not responsive to psychosocial intervention. Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R‐ but not S‐enantiomer.
View Article and Find Full Text PDFExploratory CSF proteomics biomarker outcomes of the the phase 2 clinical trial shine to assess the effects of CT1812 in Alzheimer’s patients.
Alzheimers Dement
December 2024
Cognition Therapeutics, Inc, Pittsburgh, PA, USA
Background: SHINE (NCT03507790, COG0201) is a Phase 2 randomized, double‐blind, placebo‐controlled 6‐month trial, conducted to study the effect of the sigma‐2 receptor (S2R) modulator CT1812 in patients with Alzheimer’s disease (AD). An unbiased assessment of CSF proteomes from the patients that completed the SHINE trial was performed to identify pharmacodynamic (PD) biomarkers of target/pathway engagement and disease modification for CT1812.
Method: Tandem‐mass tag mass spectrometry (TMT‐MS) CSF proteomics was performed on baseline and end of study samples from an analysis of SHINE Part A and B to test the effects of two doses (100 mg, 300 mg; given orally, once daily) of CT1812 compared to placebo in mild to moderate AD patients.
HMGA1 Plays a Role in Counteracting DNA Damage Induced by BoHV-1 Productive Infection.
Int J Mol Sci
December 2024
College of Life Sciences, Hebei University, Baoding 071002, China.
Bovine herpesvirus 1 (BoHV-1) productive infection induces the generation of DNA double-strand breaks (DSBs), which may consequently lead to cell apoptosis. In response to DSBs, the DNA damage repair-related protein 53BP1 is recruited to the sites of DSBs, leading to the formation of 53BP1foci, which are crucial for the repair of damaged DNA and maintaining genomic integrity by repairing DSBs. In this study, we discovered that HMGA1 may play a significant role in counteracting virus infection-induced DNA damage, as the siRNA-mediated knockdown of HMGA1 protein expression or inhibition of HMGA1 activity by the chemical inhibitor Netropsin uniformly exacerbates the DNA damage induced by BoHV-1 productive infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!